Clinical Results of Hypomethylating Agents in AML Treatment.

J Clin Med · 2014 · PMC4470235 · PMID 26237015

Europe PMC DOI

hedged sentence

0.0829

closest p · 1.7× alpha

0.0829

boldest claim

The sentences

did not reach statistical significancep = 0.0829so close (0.05 < p ≤ 0.1)

Median OS, the primary endpoint of the study, was 10.4 months for patients receiving azacitidine compared to 6.5 months for patients receiving CCR, which did not reach statistical significance (HR = 0.84 (95% CI 0.69–1.02), p = 0.0829).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.